GLP-1 medications have rapidly become some of the most influential treatments for Type 2 diabetes and weight loss. As more people look into these prescriptions, there is growing curiosity about how ...

Although Ozempic has gained popularity for its potential weight loss benefits, it is primarily known as one of the most well-known diabetes drugs. With its growing demand, Ozempic is currently facing ...

Semaglutide (Ozempic, Wegovy) may help reduce the risk of an opioid overdose in certain people, an emulation target trial suggested. Over a 1-year follow-up, people with comorbid type 2 diabetes and ...

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through the courts. Thousands of patients have filed lawsuits claiming the makers of ...

The SURPASS-CVOT trial—the large cardiovascular outcomes study that showed tirzepatide (Mounjaro) compared favorably with dulaglutide (Trulicity; both Eli Lilly) in patients with type 2 diabetes and ...

This is read by an automated voice. Please report any issues or inconsistencies here. After decades of public and self-imposed shame, Oprah credits a GLP-1 drug with silencing “food noise” — the ...

While insurance generally covers GLP-1s for the treatment of type 2 diabetes — though sometimes with limitations, depending on the insurance plan — far fewer insurance companies cover the medication ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday. Eli Lilly’s drug is called orforglipron. It ...

Here's how the next generation of obesity drugs getting closer to patients differs from Wegovy and Zepbound Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli ...